ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly diabetes therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2023] ($M)
Form 10-K Note 2 (legacy Diabetes grouping prior to Cardiometabolic Health rename)
Latest, Q3 2023
4,720
Period ended Sep 30, 2023
Change on a year earlier
+28.9%
3,663 in Q3 2022
History
15 quarters
Since Q1 2019
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diabetes therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2023] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2023 | Sep 30, 2023 | 4,720 | +28.9% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 5,011 | +45.7% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 4,190 | +23.7% | Form 10-Q (filed 2023-04-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 3,663 | +11.9% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 3,438 | +8.3% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 3,388 | +8.9% | Form 10-Q (filed 2023-04-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,274 | +17.6% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 3,176 | +14.3% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,111 | +4.8% | Form 10-Q (filed 2022-04-29) ↗ |
| Q3 2020 | Sep 30, 2020 | 2,783 | +2.6% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 2,779 | +0.6% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 2,969 | +16.3% | Form 10-Q (filed 2021-04-30) ↗ |
| Q3 2019 | Sep 30, 2019 | 2,712 | – | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,762 | – | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,553 | – | Form 10-Q (filed 2020-05-01) ↗ |
Breakdown
What makes up diabetes therapeutic area — worldwide revenue ($m) [legacy grouping through fy2023]
Cite this data
StockData. (2026). Eli Lilly Diabetes therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2023] ($M), quarterly Q1 2019–Q3 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_diabetes_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.